3 Marijuana Stocks to Buy If New York Legalizes Recreational Pot

The cannabis industry could soon be in a New York state of mind. Gov. Andrew Cuomo and state lawmakers continue to negotiate on a deal that could lead to the legalization of adult-use recreational marijuana. While no final agreement has been reached, it seems to be a question of when and not if.

There are several marijuana stocks that should be poised for explosive growth in the lucrative New York market. Here are three stocks to buy if and when the big state legalizes recreational marijuana.

Sign with a cannabis leaf next to "New York"

Image source: Getty Images.

1. Curaleaf Holdings

Curaleaf Holdings (OTC: CURLF) ranks as the biggest multistate cannabis operators (MSOs) in the U.S. based on market cap and revenue. It's also one of the best-positioned MSOs to win should New York legalize recreational pot.

The company currently claims a market share in New York's medical cannabis market of over 25%. That's enough to make Curaleaf the No. 1 player in the state's cannabis market right now. Curaleaf operates four retail dispensaries and one cultivation center in New York.

CEO Joe Bayern thinks that adult-use marijuana legalization in New Jersey will help push New York, as well as Connecticut and Pennsylvania, to legalize recreational marijuana. He recently stated that these markets "present an enormous growth opportunity" for Curaleaf.

Growth has been seemingly easy for the company so far. Curaleaf's revenue more than tripled year over year in Q4 and jumped 26% from the previous quarter. The company expects 2021 to be another record year. If New York legalizes adult-use cannabis, the year will likely be even better than expected.

2. Cresco Labs

Like Curaleaf, Cresco Labs (OTC: CRLBF) is a leading MSO with established operations in New York's medical cannabis market. Cresco operates four medical cannabis dispensaries in the state under its Sunnyside brand. It also has launched a medical cannabis delivery program in New York.

Cresco continues to aggressively expand into new markets. For example, the company is acquiring Bluma Wellness to move into Florida's fast-growing medical cannabis market. It also recently began selling recreational cannabis in Arizona.

The latter example offers a parallel to New York. Cresco already operated a medical cannabis dispensary in Arizona before the state legalized recreational pot. It's likely that the company would pursue a similar path should New York move forward with adult-use legalization.

One advantage that Cresco has over Curaleaf from an investing standpoint is valuation. Curaleaf's market cap is more than 3.5 times larger than Cresco's, but its revenue isn't nearly that much greater than Cresco's.

3. Ayr Wellness

There's an even more attractively valued cannabis operator that could jump into the New York market: Ayr Wellness (OTC: AYRW.F). Its shares currently trade at a lower price-to-sales multiple than any of the leading MSOs.

Ayr doesn't compete in New York's medical cannabis market right now as Curaleaf and Cresco do. However, the company expects to close on an acquisition in Q3 that will give it a presence in neighboring New Jersey. The opportunity in New York could be hard for Ayr to pass up if the state legalizes recreational marijuana.

The MSO is also moving quickly to expand into other attractive markets. Ayr's acquisition deals in Arizona and Ohio should wrap up any day now. It's also planning to purchase Liberty Health Sciences to become a major contender in Florida's medical cannabis market.

Ayr continues to generate strong revenue growth. It also consistently delivers positive and growing adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA). The stock is less of a sure thing for the New York market as Curaleaf and Cresco. However, the likelihood that Ayr will enter New York along with its relatively low valuation make it a stock investors will want to consider buying.

Here's The Marijuana Stock You've Been Waiting For
A little-known Canadian company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

And make no mistake – it is coming.

Cannabis legalization is sweeping over North America – 15 states plus Washington, D.C., have all legalized recreational marijuana over the last few years, and full legalization came to Canada in October 2018.

And one under-the-radar Canadian company is poised to explode from this coming marijuana revolution.

Because a game-changing deal just went down between the Ontario government and this powerhouse company...and you need to hear this story today if you have even considered investing in pot stocks.

Simply click here to get the full story now.

Learn more

Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Ayr Strategies Inc. and Cresco Labs Inc. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More